
|Videos|November 16, 2017
Dr. Epperla on FDA Approval of Frontline Obinutuzumab in Follicular Lymphoma
Author(s)Narendranath Epperla, MBBS, MS
Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.
Advertisement
Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5



































